Real-world treatment patterns and outcomes in patients with HR+/HER2− metastatic breast cancer treated with chemotherapy in the United States-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real-world treatment patterns and outcomes in patients with HR+/HER2− metastatic breast cancer treated with chemotherapy in the United States

Published:2024-09 Issue:9 Volume:9 Page:103691
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Tolaney S.M.^ORCID,Punie K.^ORCID,Carey L.A.^ORCID,Kurian A.W.^ORCID,Ntalla I.,Sjekloca N.,Shah A.,Rehnquist M.K.,Stokes M.^ORCID,Fraeman K.^ORCID,Verret W.,Jhaveri K.^ORCID

Funder

Gilead Sciences Inc

Memorial Sloan Kettering Cancer Center

Publisher

Elsevier BV

Reference43 articles.

1. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline Update;Wolff;J Clin Oncol,2023

2. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer;Gennari;Ann Oncol,2021

3. De novo and recurrent metastatic breast cancer - a systematic review of population-level changes in survival since 1995;Lord;EClinicalMedicine,2022

4. Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer;Wangchinda;World J Surg Oncol,2016

5. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V;Colleoni;J Clin Oncol,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP